Gain Therapeutics (GANX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

GANX Gain Therapeutics

Watchlist

1.710
+0.020+1.18%

Trading Nov 19 11:23 ET

45.36MMarket Cap-1598P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Chardan Capital Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsNov 19 03:36 ET · Ratings
Gain Therapeutics Advances Parkinson's Therapy Development
TipRanksNov 18 22:57 ET
Gain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson's Disease
TipRanksNov 18 20:05 ET · Ratings
Gain Therapeutics Reports Q3 EPS (17c), Consensus (21c)
TipRanksNov 14 16:21 ET
Express News | Gain Therapeutics Q3 2024 GAAP EPS $(0.17) Beats $(0.21) Estimate
BenzingaNov 14 16:17 ET
Gain Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 14 16:11 ET · Announcements

Comments

Stock_Drift

Nov 14 18:01

After Hours Ticks. 7:00pm

$Mercurity Fintech (MFH.US)$ $Freightos (CRGO.US)$ $1847 Holdings (EFSH.US)$ $MediciNova (MNOV.US)$ $Despegar.com (DESP.US)$ $NextPlat (NXPL.US)$ $Legacy Education (LGCY.US)$ $Gain Therapeutics (GANX.US)$ $Red Cat Holdings (RCAT.US)$ $Siyata Mobile (SYTA.US)$ $Innovation Beverage Group (IBG.US)$ $Greenidge Generation (GREE.US)$ $The Arena Group (AREN.US)$
📊⚡️📊

Stock_Drift

Oct 30 17:49

After Hours Ticks. 6:48pm

$Gain Therapeutics (GANX.US)$ $Orion Group (ORN.US)$ $Nextracker (NXT.US)$ $Alphatec (ATEC.US)$ $Remitly Global (RELY.US)$ $1847 Holdings (EFSH.US)$ $Carvana (CVNA.US)$ $Junee (JUNE.US)$ $Tenon Medical (TNON.US)$ $Aditxt (ADTX.US)$ $CPS Technologies (CPSH.US)$ $Root Inc (ROOT.US)$
📊⚡️📊

Jaguar8

Oct 7 06:01

NEWS

$Gain Therapeutics (GANX.US)$
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
Gain Therapeutics presented new preclinical data for GT-02287 at the Society for Neuroscience 2024 conference. The data demonstrates disease-modifying activity in both GBA-1 and idiopathic Parkinson's disease models. Key findings include:
1. Persistent rescue of motor and cognitive function after GT-02287 discontinuation
2. Improved mitochondrial function and neuroprotection in GBA1-Parkins...

Trytosaveabit

Sep 30 06:37

Update

$Gain Therapeutics (GANX.US)$ Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
Gain Therapeutics, Inc. Mon, Sep 30, 2024, 7:00 AM 7 min read
Gain Therapeutics, Inc.
GT-02287 Increases Peripheral GCase Activity
GT-02287 Demonstrates CNS Exposure